Profile data is unavailable for this security.
About the company
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
- Revenue in DKK (TTM)9.16bn
- Net income in DKK6.54bn
- Incorporated1997
- Employees440.00
- LocationZealand Pharma A/SSydmarken 11SOEBORG 2860DenmarkDNK
- Phone+45 88773600
- Fax+45 88773898
- Websitehttps://www.zealandpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioArctic AB | 1.35bn | 705.19m | 16.87bn | 122.00 | 28.51 | 14.50 | 22.98 | 12.48 | 11.30 | 11.30 | 21.64 | 22.22 | 1.04 | -- | -- | 17,909,460.00 | 54.12 | -2.87 | 67.19 | -3.22 | 97.08 | 86.59 | 52.17 | -12.41 | -- | -- | 0.0231 | -- | -58.22 | -1.80 | -177.24 | -- | 52.19 | -- |
| Genus plc | 5.78bn | 165.81m | 17.32bn | 3.17k | 105.43 | 4.20 | 31.11 | 3.00 | 0.2874 | 0.2874 | 10.07 | 7.21 | 0.7132 | -- | 6.12 | 212,239.80 | 2.05 | 2.91 | 2.40 | 3.43 | -- | -- | 2.87 | 4.28 | 1.32 | 7.89 | 0.3584 | 70.94 | 0.5981 | 4.06 | 144.30 | -11.37 | -8.94 | 1.92 |
| BB BIOTECH AG | 4.30bn | 1.36bn | 20.87bn | 86.00 | 15.23 | 1.10 | -- | 4.85 | 3.02 | 3.02 | 9.58 | 41.83 | 0.2179 | -- | -- | 6,103,396.00 | 6.90 | -1.24 | 7.32 | -1.35 | 99.84 | 97.19 | 31.65 | -39.47 | -- | 1.50 | 0.00 | -- | 21,076.79 | -31.20 | 136.74 | -35.45 | -- | -11.94 |
| Zealand Pharma A/S | 9.16bn | 6.54bn | 28.58bn | 440.00 | 4.39 | 1.85 | 4.35 | 3.12 | 91.00 | 91.00 | 129.24 | 215.72 | 0.6929 | 3.05 | 75.81 | 27,328,360.00 | 49.52 | -32.33 | 52.34 | -36.49 | 99.99 | 95.31 | 71.47 | -515.03 | 14.10 | -- | 0.0261 | -- | -81.71 | 8.69 | -53.30 | -- | -10.98 | -- |
| BACHEM HOLDING AG | 5.56bn | 1.10bn | 39.51bn | 2.29k | 35.76 | 3.54 | 27.76 | 7.11 | 1.80 | 1.80 | 9.07 | 18.14 | 0.3733 | 1.05 | 4.37 | 307,174.00 | 7.39 | 8.26 | 8.60 | 9.44 | 31.23 | 31.55 | 19.79 | 20.06 | 0.781 | 12.09 | 0.0428 | 52.54 | 4.84 | 14.05 | 7.50 | 17.29 | 56.91 | 7.21 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 3.46m | 4.84% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.75m | 3.84% |
| Capital International Ltd.as of 05 Feb 2026 | 2.60m | 3.64% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 2.51m | 3.51% |
| Polar Capital LLPas of 31 Dec 2025 | 2.39m | 3.35% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.57m | 2.19% |
| Schroder Investment Management Ltd.as of 31 Dec 2025 | 1.37m | 1.91% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.02m | 1.43% |
| TIAA-CREF Investment Management LLCas of 31 Dec 2025 | 935.14k | 1.31% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 871.33k | 1.22% |
